CN109475623B - 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案 - Google Patents

用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案 Download PDF

Info

Publication number
CN109475623B
CN109475623B CN201780032450.0A CN201780032450A CN109475623B CN 109475623 B CN109475623 B CN 109475623B CN 201780032450 A CN201780032450 A CN 201780032450A CN 109475623 B CN109475623 B CN 109475623B
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
acid sequence
bdca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780032450.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109475623A (zh
Inventor
M.R.H.克雷布斯
D.戴
S.苏尔
D.拉巴
D.马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to CN202310503830.5A priority Critical patent/CN116850282A/zh
Publication of CN109475623A publication Critical patent/CN109475623A/zh
Application granted granted Critical
Publication of CN109475623B publication Critical patent/CN109475623B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780032450.0A 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案 Active CN109475623B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310503830.5A CN116850282A (zh) 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310503830.5A Division CN116850282A (zh) 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案

Publications (2)

Publication Number Publication Date
CN109475623A CN109475623A (zh) 2019-03-15
CN109475623B true CN109475623B (zh) 2023-05-26

Family

ID=58672794

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780032450.0A Active CN109475623B (zh) 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案
CN202310503830.5A Pending CN116850282A (zh) 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310503830.5A Pending CN116850282A (zh) 2016-04-28 2017-04-27 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案

Country Status (14)

Country Link
US (2) US20190284281A1 (https=)
EP (1) EP3448425A1 (https=)
JP (3) JP7045327B2 (https=)
KR (5) KR20240033168A (https=)
CN (2) CN109475623B (https=)
AU (2) AU2017258191B2 (https=)
CA (1) CA3022116A1 (https=)
CO (1) CO2018012506A2 (https=)
EA (1) EA201892443A1 (https=)
IL (2) IL262514B2 (https=)
MA (1) MA44763A (https=)
MX (3) MX2018012945A (https=)
PH (1) PH12018502278A1 (https=)
WO (1) WO2017189827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CA3203971A1 (en) 2020-12-03 2022-06-09 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
EP4385525A1 (en) 2021-08-09 2024-06-19 Inventera Inc. Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
CN120475994A (zh) * 2022-12-28 2025-08-12 映恩生物科技(上海)有限公司 抗bdca2抗体-药物偶联物及其用途
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN105452295A (zh) * 2012-12-10 2016-03-30 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN105452295A (zh) * 2012-12-10 2016-03-30 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途

Also Published As

Publication number Publication date
CA3022116A1 (en) 2017-11-02
IL262514B1 (en) 2025-08-01
MA44763A (fr) 2019-03-06
KR20190002563A (ko) 2019-01-08
EA201892443A1 (ru) 2019-04-30
IL321561A (en) 2025-08-01
US20250289895A1 (en) 2025-09-18
US20190284281A1 (en) 2019-09-19
JP7045327B2 (ja) 2022-03-31
MX2018012945A (es) 2019-03-06
IL262514A (en) 2018-12-31
KR20250088784A (ko) 2025-06-17
KR20240159012A (ko) 2024-11-05
NZ747504A (en) 2025-08-29
AU2024203240A1 (en) 2024-06-13
CN116850282A (zh) 2023-10-10
KR102366547B1 (ko) 2022-02-23
JP2022084782A (ja) 2022-06-07
IL262514B2 (en) 2025-12-01
CN109475623A (zh) 2019-03-15
KR20220028150A (ko) 2022-03-08
EP3448425A1 (en) 2019-03-06
AU2017258191A1 (en) 2018-11-15
JP2024038308A (ja) 2024-03-19
CO2018012506A2 (es) 2018-12-14
PH12018502278A1 (en) 2019-09-09
WO2017189827A1 (en) 2017-11-02
MX2025000037A (es) 2025-02-10
MX2023008075A (es) 2023-07-18
AU2017258191B2 (en) 2024-06-13
BR112018072125A2 (pt) 2019-03-19
KR20240033168A (ko) 2024-03-12
NZ787392A (en) 2025-08-29
JP2019520316A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
CN109475623B (zh) 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案
US20240091354A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
KR20220047826A (ko) 고 농도의 항-c5 제형
EP4151233A1 (en) Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof
CN112804989A (zh) 抗fgfr2抗体制剂
TW202345902A (zh) 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
WO2023198115A1 (en) Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof
BR112018072125B1 (pt) Composição farmacêutica e seringa, injetor ou bomba
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
CA3246509A1 (en) ANTI-ILT4 COMPOSITIONS AND METHODS
HK40052955A (zh) 抗fgfr2抗体制剂
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment